>_ QFI Terminal
TerminalStocks › TMDX

TransMedics Group, Inc. (TMDX) Stock

Healthcare · Medical - Devices · US
$78.79 +7.61%
Last updated Jun 19, 2026 00:00 UTC

TMDX Key Statistics

Market Cap$2.72B
P/E (TTM)18.03
P/S (TTM)4.28
P/B (TTM)5.48
Revenue (TTM)$635.89M
EPS (TTM)$4.37
Dividend Yield
ROE (TTM)41.92%
Net Margin27.04%
Gross Margin59.09%
52W High$156.00
52W Low$60.11
Analyst ViewBuy
Price Target$120.20
Employees728
Volume1,719,376

About TransMedics Group, Inc.

TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.

CEO: Waleed H. Hassanein. Company website

See TMDX live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open TMDX in Terminal See plans

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corporation MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.